Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
14/08/202415:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
14/08/202415:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INTEUIntegral Acquisition Corporation 1
14/08/202415:11Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBUSOTC:SKVISkinvisible Inc (QB)
14/08/202415:10Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:JPM-MJP Morgan Chase and Co
14/08/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GVPGSE Systems Incorporated
14/08/202415:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRTSAlpha Tau Medical Ltd
14/08/202415:10Business WireCentral Securities Corporation Releases Report to StockholdersAMEX:CETCentral Securities Corp
14/08/202415:10PR Newswire (US)VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business UpdateAMEX:VNRXVolitionRX Limited
14/08/202415:10GlobeNewswire Inc.Cemtrex Reports Third Quarter 2024 Financial ResultsNASDAQ:CETXWCemtrex Inc
14/08/202415:10GlobeNewswire Inc.Enthusiast Gaming Reports Q2 2024 ResultsTSX:EGLXEnthusiast Gaming Holdings Inc
14/08/202415:10GlobeNewswire Inc.Rivalz Network Secures $9 Million to Advance AI Intel Infrastructure
14/08/202415:10GlobeNewswire Inc.Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/08/202415:10GlobeNewswire Inc.Golden Heaven Group Holdings Ltd. Announces Receipt of Nasdaq Delisting Determination and Plans to AppealNASDAQ:GDHGGolden Heaven Group Holdings Ltd
14/08/202415:10GlobeNewswire Inc.Beneficient Reports Results For First Quarter Fiscal 2025NASDAQ:BENFBeneficient
14/08/202415:10GlobeNewswire Inc.Stryve Foods, Inc. Reports Fiscal 2024 Second Quarter ResultsNASDAQ:SNAXStryve Foods Inc
14/08/202415:09Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TBRGTruBridge Inc
14/08/202415:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ABBVAbbVie Inc
14/08/202415:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:APHAmphenol Corp
14/08/202415:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:NHINational Health Investors Inc
14/08/202415:08PR Newswire (US)The Berwyn Group Launches Berwyn University: A Resource Hub for industry information
14/08/202415:07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:HTLFPHeartland Financial USA Inc
14/08/202415:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:CHWYChewy Inc
14/08/202415:07Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNASDAQ:NVDANVIDIA Corporation
14/08/202415:07GlobeNewswire Inc.Lulus Reports Second Quarter 2024 ResultsNASDAQ:LVLULulus Fashion Lounge Holdings Inc
14/08/202415:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:EMKREMCORE Corporation
14/08/202415:05GlobeNewswire Inc.Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business UpdatesNASDAQ:GNLXGenelux Corporation
14/08/202415:05GlobeNewswire Inc.StoneCo Reports Second Quarter 2024 ResultsNASDAQ:STNEStoneCo Ltd
14/08/202415:05GlobeNewswire Inc.Ingredion Named a Finalist for the National Safety Council's Green Cross for Safety® AwardsNYSE:INGRIngredion Incorporated
14/08/202415:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TBRGTruBridge Inc
14/08/202415:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELYMEliem Therapeutics Inc